Navigation Links
DiagnoCure to present at the JMP Securities Healthcare Focus Conference on October 6, 2008
Date:10/1/2008

Ticker Symbol: CUR

QUEBEC CITY, Oct. 1 /PRNewswire-FirstCall/ - DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced today that Mr. John Schafer, President and CEO of the Company, will be presenting a company overview at the Third Annual JMP Securities Healthcare Focus Conference on Monday, October 6, 2008, at 1:30 PM (ET). This conference is taking place in New York (New York) on October 6 and 7, 2008.

The event will be webcast live through DiagnoCure's website at http://www.diagnocure.com, through a link on the Investors page - Presentations and Conferences. An archived presentation will be available on the Web site for 90 days.

More information on the Third Annual JMP Securities Healthcare Focus Conference can be found at http://www.jmpsecurities.com.

About DiagnoCure

DiagnoCure (TSX: CUR) is a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services that increase clinician and patient confidence in making critical treatment decisions. DiagnoCure Oncology Laboratories, a subsidiary of DiagnoCure Inc., recently launched the Previstage(TM) GCC Colorectal Cancer Staging Test, the first GCC-based molecular test for the management of colorectal cancer. The Company also has a strategic alliance with Gen-Probe (NASDAQ: GPRO) for the development and commercialization of a second-generation prostate cancer test using PCA3, DiagnoCure's proprietary molecular marker. This test is also available through laboratories in the U.S. using PCA3 analyte specific reagents (ASR) from Gen-Probe, in Europe as the CE-marked PROGENSA(TM) PCA3 in vitro assay, and in Canada. In addition to its own research, the Company intends to acquire or in-license additional promising cancer biomarkers from
'/>"/>

SOURCE DIAGNOCURE INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. DiagnoCures molecular diagnostic tests - PCA3 and GCC - discussed at scientific meetings
2. DiagnoCure to host Q2 2008 earnings conference call and webcast
3. DiagnoCure announces second quarter 2008 results
4. DiagnoCures GCC marker for the staging of colorectal cancer discussed at the Eastern Cooperative Oncology Group
5. Diagnocure announces sponsorship of inaugural undy 5,000 run - Partnership with the Colon Cancer Alliance creates patient awareness of previstage(TM) GCC staging test
6. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
7. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
8. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
9. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
10. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
11. AtriCure to Present at Roth Capital Partners 2007 New York Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... Gerald “Solutionman” Haman surveyed over 10,000 people ... innovative thinking. “The #1 block was lack of ... reports Haman, who created the Thinkubator Innovation Studio in ... that they did not have enough time for innovative ... stimulate innovation. , Solutionman’s monthly “Accelerating Innovation Training” workshops ...
(Date:2/28/2015)... The Classic Denture Center , located ... Throughout all of March patients can receive $25 ... service can help overall mouth health and give ... notice certain symptoms that suggest the denture teeth are ... , 1.    Pain, clicking, and popping in the joints, 2.    Pain ...
(Date:2/28/2015)... Vancouver personal injury lawyers at Jiwa Law ... by time limits. They stated that in many cases, missing ... even nullify it. Many a time, delays in making an ... under BC law. As a result, experts at Jiwa Law ... consult a personal injury lawyer in order to know more ...
(Date:2/28/2015)... For those people who are unable ... Mesothelioma Applied Research Foundation (Meso Foundation) will broadcast ... starting at 9:30 AM. , The live broadcast is ... can be accessed through any browser on a computer ... Symposium is a unique event that covers important treatment ...
(Date:2/28/2015)... 28, 2015 National Sales ... sales, marketing and supply chain management for consumer ... is bringing its award winning solutions for thinning-damaged ... products are specifically created to combat thinning-damaged hair. ... is committed to marrying science with nature to ...
Breaking Medicine News(10 mins):Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 2Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3
... later on, study suggests , , WEDNESDAY, March 26 (HealthDay ... linked to a softening of bones in a baby,s ... breast-feeding without vitamin D supplementation could prolong the deficiency, ... problems later in life, including decreased bone density and ...
... be the largest study of its kind for the genetic ... Crohns Disease as well as further evidence that some people ... The study examined changes in DNA associated with the two ... (CD), which is most frequently marked by inflammation of the ...
... BD (Becton,Dickinson and Company) (NYSE: BDX ) ... its second fiscal quarter 2008 earnings conference call on,Wednesday, ... issue a press release,detailing the quarter,s earnings earlier that ... be accessible through BD,s,website at http://www.bd.com/investors and ...
... of pediatric liver transplant recipients report lower health-related ... after the surgery, compared to reports from the ... dysfunction fall within the normal range. These findings ... Transplantation. The article is also available online at ...
... From the Underbelly, star Rachael Harris and ,Iron Chef, judge and,Mom-a-licious creator ... ... fundraiser, LOS ANGELES, March 26 The Fourth Annual Open Toe Shoe,Party ... Santa,Monica Hotel. The event will raise funds for The One Small Voice,Foundation., ...
... Adolescents receiving,comprehensive sex education had a substantially lower ... abstinence-only education or no,education at all, according to ... Adolescent Health., The study, conducted by Pamela ... E. Lafferty, M.D., also concluded that teaching about,contraception ...
Cached Medicine News:Health News:Too Little Vitamin D May Soften Baby's Skull 2Health News:Large multicenter study suggests new genetic markers for Crohn's disease 2Health News:Study shows lifetime effects of pediatric liver transplants 2Health News:Celebrities From All Walks of Life Put Their Best Foot Forward for the Fourth Annual Open Toe Shoe Party 2Health News:New Study -- Same Result! Comprehensive Sex Education Works 2
(Date:2/27/2015)... Feb. 27, 2015  PTC Therapeutics, Inc. (NASDAQ: ... reported financial results for the fourth quarter and full ... was a transformative year for PTC. We are now ... developing RNA-targeted therapies in the rare disease space," stated ... Inc. "We are proud to bring the first treatment ...
(Date:2/27/2015)... and JERUSALEM , Feb. 27, 2015 ... octreotide capsules, its lead product for the orphan condition ... Series E financing round. Participants in the financing included ... an undisclosed blue chip public investment fund, as well ... Health Ventures, Abingworth and ARCH Venture Partners. ...
(Date:2/26/2015)... 26, 2015  AbbVie (NYSE: ABBV ... in its neuroscience and oncology development programs have ... American Academy of Neurology annual meeting in ... 18-25. The accepted abstracts feature results from studies ... investigational treatments in AbbVie,s pipeline. Presentations will include ...
Breaking Medicine Technology:PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 2AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 4AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 5AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 6AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 7
... Biotech AB,(Stockholm:ACTI.ST) and Chelsea Therapeutics International Ltd,(NASDAQ:CHTP) ... of an,I-3D compound. , The aim of ... of the compound in humans. The trial ... demonstrated that the selected I-3D compound,(ABR-224050) has ...
... PALO ALTO, Calif., March 14, 2007 /PRNewswire-FirstCall/ -- ... the of,Cardiology (JACC) has published data from the ... therapy with,Ranexa(R) (ranolazine extended-release tablets) to be safe ... who completed one,of two phase 3 clinical trials, ...
Cached Medicine Technology:Active Biotech's I-3D Micro-dosing Clinical Trial Concluded 2JACC Publishes Long-Term Safety and Tolerability Data from,Ranolazine Open Label Experience (ROLE) Program 2JACC Publishes Long-Term Safety and Tolerability Data from,Ranolazine Open Label Experience (ROLE) Program 3JACC Publishes Long-Term Safety and Tolerability Data from,Ranolazine Open Label Experience (ROLE) Program 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: